Clinical trials: Hematological Neoplasm
CLL/SLL, NHL
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
- Conditions
- CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT05665062
- Testing
- SYNCAR-001, STK-009, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Synthekine
Hematologic Diseases, Hematologic Malignancies
Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
The purpose of this study is to determine the maximum tolerated dose and evaluate the safety of the administration of donor lymphocytes depleted of alloreactive T-cells following a stem cell transplant from a related…
- Trial name
- NCT00993486
- Testing
- Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Kiadis Pharma
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML
- Trial name
- TWT-202 (NCT04730258)
- Testing
- CFI-400945, Azacitidine
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 72 people
- Sponsor
- Treadwell Therapeutics, Inc
Leukemia
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
The purpose of this study was to determine the efficacy and safety of twice daily (bid) oral midostaurin in patients with Aggressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia (MCL) with or without an Associated…
- Trial name
- NCT00782067
- Testing
- Midostaurin (PKC412)
- Where
- 29 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Multiple Myeloma
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
To assess safety and tolerability, describe the dose-limiting toxicities, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a…
- Conditions
- Acute Myeloid Leukemia, Multiple Myeloma, Diffuse Large B-cell Lymphoma
- Trial name
- NCT03106428
- Testing
- MEDI7247
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 67 people
- Sponsor
- MedImmune LLC
AML/MDS, CD33 Expressing Hematological Malignancies
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
- Conditions
- AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
- Trial name
- NCT06325748
- Testing
- SENTI-202
- Where
- 8 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Senti Biosciences
Polycythemia Vera
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
This is a Phase 2 study with an open-label dose escalation phase followed by a blinded withdrawal phase and an open label extension.
- Trial name
- NCT04057040
- Testing
- PTG-300
- Where
- 16 sites in United States, India
- Volunteers
- 70 people
- Sponsor
- Protagonist Therapeutics, Inc.
Hematologic Malignancy, Non Hodgkin Lymphoma
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
The purpose of this single- arm, open-label, dose escalation and dose expansion phase I/II study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-814 in patients with hematological…
- Conditions
- Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult
- Trial name
- NCT06206174
- Testing
- TGRX-814
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Non-hematologic Malignancies, Metastatic Melanoma
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Temozolomide (chemotherapy) in treating patients with solid tumors, including metastatic melanoma (MM), BRCA deficient…
- Conditions
- Non-hematologic Malignancies, Metastatic Melanoma, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00526617
- Testing
- ABT-888, Temozolomide
- Volunteers
- 41 people
- Sponsor
- AbbVie
CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoproliferative disorders.
- Conditions
- CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma
- Trial name
- NCT00788684
- Testing
- rituximab, ABT-263
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- AbbVie
Hematologic Neoplasm, Neoplasms
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Rollover study supporting hematological disorder indications from Celgene sponsored CC-486 (oral azacitidine) protocols eligible for participation in the study.
- Conditions
- Hematologic Neoplasm, Neoplasms, Hematologic Malignancies
- Trial name
- NCT02494258
- Testing
- CC-486
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Celgene
Hematologic Malignancy
A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
This is a phase I study to evaluate the safety ,Tolerability, PK, PD, and preliminary efficacy of BC3402 Monotherapy in MDS or CMML, and explore the RP2D/MTD dose.
- Trial name
- NCT05690425
- Testing
- BC3402 Injection
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Polycythemia Vera
Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera
This is a prospective observational study that will enroll patients with high-risk Polycythemia Vera (PV) with at least one Thromboembolic Event (TE) after diagnosis or up to 2 years prior to diagnosis.
- Trial name
- Prospero (NCT05548062)
- Testing
- Hydroxyurea, Ruxolitinib
- Where
- 33 sites in Italy
- Volunteers
- 242 people
- Sponsor
- Novartis Pharmaceuticals
Sarcoma, Neuroblastoma
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Background: Marqibo(Registered Trademark) is a new anticancer drug. It combines Vincristine sulfate, which is a widely used anticancer drug, and packages it into a tiny fat bubble known as a liposome.
- Conditions
- Sarcoma, Neuroblastoma, Wilms Tumor, Leukemia
- Trial name
- NCT01222780
- Testing
- Marqibo
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Acrotech Biopharma Inc.
Blood And Marrow Transplantation, Leukemia
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
The goal of this clinical research study is to learn if it is safe and feasible to transplant patients with one of two units of cord blood that has been changed in the laboratory before it is given.
- Conditions
- Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection
- Trial name
- NCT01983761
- Testing
- Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative), Fludarabine, Melphalan, ATG (Reduced Intensity)
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Targazyme, Inc.
Myeloproliferative Neoplasm
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
There are 5 parts to this study for which the primary objectives are to evaluate safety, tolerability, and pharmacokinetics (PK) of navitoclax when administered alone (Part 1) or when administered in combination with ruxolitinib…
- Trial name
- NCT04041050
- Testing
- Navitoclax, Ruxolitinib, Celecoxib
- Where
- 42 sites in United States, Belgium and 12 more
- Volunteers
- 85 people
- Sponsor
- AbbVie
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT03833180
- Testing
- Zilovertamab vedotin
- Where
- 14 sites in United States
- Volunteers
- 91 people
- Sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Hodgkin Disease, Lymphoma, Non-Hodgkin
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) using a non-randomized study design in participants with the following hematological malignancies: classical…
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
- Trial name
- NCT03598608
- Testing
- pembrolizumab, Favezelimab
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 137 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
The main purpose of this first human study with CC-115 is to assess the safety and action of a new class of experimental drug (dual DNA-PK and TOR kinase inhibitors) in patients with advanced tumors unresponsive to standard…
- Conditions
- Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma
- Trial name
- NCT01353625
- Testing
- CC-115
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 118 people
- Sponsor
- Celgene
Hematologic Malignancy, Solid Malignancy
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies
- Trial name
- NCT06208878
- Testing
- Non Interventional
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 70 people
- Sponsor
- CRISPR Therapeutics AG